Novartis

Novartis Lands FDA Approval for Afinitor in Advanced Breast Cancer

The tablets have been approved for treatment of postmenopausal women in combination with exemestane.

The US Food and Drug Administration (FDA) has approved Afinitor (everolimus) tablets for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ breast cancer) in combination with exemestane after failure of treatment with letrozole or anastrozole.

No votes yet

Novartis Receives Approval in Japan for Two Innovative Therapies, Gilenya in MS and Ilaris in CAPS

 
Gilenya first high efficacy oral therapy approved in Japan for the prevention of relapse and delay of progression of physical disability in adults with multiple sclerosis (MS) Ilaris the first drug approved in Japan for the treatment of cryopyrin-associated periodic syndrome (CAPS), a rare and debilitating auto inflammatory disease Approvals demonstrate ongoing Novartis commitment to bringing innovative treatments to patients in Japan
 
 

No votes yet

Novartis Increases Growth Potential Through Integration of Alcon

Alcon is innovative new growth platform with leading position in eye care segment
 

No votes yet
Syndicate content